KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ionis Pharmaceuticals (IONS) over the last 16 years, with Q3 2025 value amounting to $159.8 million.

  • Ionis Pharmaceuticals' Shares Outstanding (Weighted Average) rose 751.85% to $159.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.8 million, marking a year-over-year increase of 751.85%. This contributed to the annual value of $149.5 million for FY2024, which is 441.65% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Shares Outstanding (Weighted Average) is $159.8 million, which was up 751.85% from $159.1 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $159.8 million during Q3 2025, with a 5-year trough of $140.8 million in Q1 2021.
  • Over the past 5 years, Ionis Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $143.1 million (recorded in 2023), while the average stood at $145.8 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 57.46% in 2022, then soared by 906.77% in 2025.
  • Ionis Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $141.0 million in 2021, then grew by 0.59% to $141.8 million in 2022, then increased by 0.95% to $143.2 million in 2023, then increased by 4.42% to $149.5 million in 2024, then grew by 6.86% to $159.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $159.8 million for Q3 2025, versus $159.1 million for Q2 2025 and $158.7 million for Q1 2025.